Effect of volume support, antibiotic therapy, and monoclonal antiendotoxin antibodies on mortality rate and blood concentrations of endothelin and other mediators in fulminant intra-abdominal sepsis in rats

Crit Care Med. 1995 Aug;23(8):1382-90. doi: 10.1097/00003246-199508000-00012.

Abstract

Objective: To study the therapeutic effects of volume support, antibiotics, and a monoclonal antiendotoxin antibody on the mortality rate and blood concentrations of endothelin and other mediators in fulminant intra-abdominal sepsis in rats.

Design: Prospective, randomized, controlled trial.

Setting: Research laboratory in a university hospital.

Subjects: Adult male Wistar rats.

Interventions: Fulminant polymicrobial intra-abdominal sepsis was induced by a 4-mm cecal perforation. Treatment was performed with saline volume support, the antibiotic imipenem/cilastatin, and the monoclonal antiendotoxin antibody E5, both as monotherapy and as a combined regimen. Mortality rates were recorded and concentrations of bacteria, endotoxin, tumor necrosis factor (TNF), big endothelin, and endothelin-1 (21 amino acids) in blood were determined.

Measurements and main results: Substantial increases in circulating big endothelin and endothelin-1 concentrations were observed during sepsis. The combination of volume support with antibiotics reduced the mortality rate, but neither as monotherapy nor as a combined regimen did this intervention modify plasma endothelin-1 concentrations. This finding suggests that hypovolemia and bacteria per se are not important stimuli for endothelin synthesis and a high plasma level of endothelin-1 does not necessarily predict poor outcome in sepsis. The inactive big endothelin is enzymatically cleaved, leaving the biologically active 21-residue endothelin-1. Intervention with E5 substantially reduced the mortality rate and concentrations of endotoxin, TNF, and plasma endothelin-1, while big endothelin and total endothelin immunoreactivity did not decrease. This finding indicates a suppressed conversion of big endothelin to endothelin-1 after E5 treatment. Because E5 has no direct effect on endothelin metabolism, E5 probably reduces the synthesis of endothelin-1 by suppressing the endothelin-activators endotoxin and TNF. A triple combination of volume support, imipenem/cilastatin, and E5 was the only regimen that reduced all of the end points: mortality rate, hemoconcentration, bacteria, endotoxin, TNF, and endothelin-1.

Conclusions: The concentration of plasma endothelin was increased during fulminant intra-abdominal sepsis in rats. Combining volume support with antibiotic therapy reduced the mortality rate, but did not modify concentrations of plasma endothelin-1. The monoclonal antiendotoxin antibody E5 reduced the mortality rate and concentrations of endotoxin, TNF, and endothelin-1, but not big endothelin. This finding indicates that E5 therapy inhibits the conversion of big endothelin to 21-residue endothelin-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Blood Volume
  • Cilastatin / therapeutic use
  • Cilastatin, Imipenem Drug Combination
  • Combined Modality Therapy
  • Drug Combinations
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination / therapeutic use*
  • Endothelins / blood*
  • Fluid Therapy / methods*
  • Imipenem / therapeutic use
  • Immunoglobulins / therapeutic use*
  • Male
  • Peritonitis / blood
  • Peritonitis / mortality
  • Peritonitis / therapy
  • Prospective Studies
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Sepsis / blood
  • Sepsis / mortality
  • Sepsis / therapy*
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Drug Combinations
  • Endothelins
  • Immunoglobulins
  • antilipopolysaccharide antibodies
  • Cilastatin
  • Imipenem
  • Cilastatin, Imipenem Drug Combination